Eton Pharmaceuticals Inc (ETON) Stock Analysis
Verdict: HOLD
Profitability pivot and peak sales guidance of $500M drive a parabolic breakout, but extreme valuation and insider selling demand caution.
Investment score: 64/100
Analysis as of
Is Eton Pharmaceuticals Inc stock worth reviewing? AI model thesis
Eton has successfully transitioned to a profitable commercial orphan drug company, but the current price reflects nearly 3 years of perfect execution.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 80/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Eton Pharmaceuticals Inc opportunities and risks
What speaks for ETON
- $500M Peak Sales Target
What speaks against ETON
- Aggressive Technical Overextension
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ETON | 126.6x | 15.3x | 85.9x | 57.9% | 12.0% | 0.9% |
| KARD | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.1% |
| TRLV | n/a | 1.7x | 7.0x | 54.6% | -7.0% | 12.0% |
| ANIP | 15.8x | 1.8x | 6.7x | 65.2% | 10.8% | 9.2% |
| AVLN | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| LBRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
Frequently asked questions about Eton Pharmaceuticals Inc (ETON)
Is ETON stock a good investment?
The cached TradeMates AI model rates Eton Pharmaceuticals Inc as HOLD with an investment score of 64/100. Eton has successfully transitioned to a profitable commercial orphan drug company, but the current price reflects nearly 3 years of perfect execution. This is algorithmic model output, not personal investment advice.
Is ETON stock a buy?
The TradeMates model verdict for ETON is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.